Open-label, Multicenter, Dose-escalating Phase II Study to Investigate the Safety, Tolerability, and Early Signs of Efficacy of Subcutaneous Administrations of Tadekinig Alfa (IL-18BP) in Patients With Adult -Onset Still's Disease (AoSD) During 12 Weeks

Trial Profile

Open-label, Multicenter, Dose-escalating Phase II Study to Investigate the Safety, Tolerability, and Early Signs of Efficacy of Subcutaneous Administrations of Tadekinig Alfa (IL-18BP) in Patients With Adult -Onset Still's Disease (AoSD) During 12 Weeks

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Tadekinig alfa (Primary)
  • Indications Adult-onset Still's disease
  • Focus Adverse reactions
  • Sponsors AB2 Bio
  • Most Recent Events

    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 29 Aug 2016 Number of treatment arms changed from 3 to 2.
    • 29 Aug 2016 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top